ArticleCureus2026
Obinutuzumab Treatment in Rituximab- and Bortezomib-Resistant Phospholipase A2 Receptor Antibody-Positive Membranous Nephropathy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary membranous nephropathy (MN) is a frequent cause of nephrotic syndrome in adults and is commonly linked to circulating autoantibodies against the M-type phospholipase A2 receptor (PLA2R). Rituximab has proven effective as a B-cell-depleting therapy in many patients; however, a significant proportion eventually develop resistance. We report the case of a 54-year-old man with PLA2R antibody-positive primary MN who did not respond to multiple immunosuppressive therapies, including cyclophosphamide, calcineurin inhibitors, repeated rituximab courses, and bortezomib. Despite ongoing nephrotic syndrome and declining renal function, treatment with obinutuzumab resulted in rapid and sustained clinical improvement. This was associated with a substantial reduction in proteinuria, normalization of serum albumin, and recovery of renal function. Our findings suggest that obinutuzumab may offer an effective therapeutic option for highly refractory PLA2R antibody-positive MN and that achieving more complete B-cell depletion could overcome resistance to conventional anti-CD20 therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.